[{"id":"4695b874-0dda-42f4-8cd0-07e18a81aa76","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923013","created_at":"2021-01-18T03:34:20.113Z","updated_at":"2024-07-02T16:34:38.035Z","phase":"Phase 2","brief_title":"Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia","source_id_and_acronym":"NCT00923013","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD22 • ITGAX","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD22 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cladribine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 203","initiation":"Initiation: 10/20/2008","start_date":" 10/20/2008","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-05"},{"id":"7751beea-ed0b-4a4d-8397-acffe8af0a14","acronym":"","url":"https://clinicaltrials.gov/study/NCT02432378","created_at":"2021-01-18T11:38:27.441Z","updated_at":"2024-07-02T16:35:00.114Z","phase":"Phase 1/2","brief_title":"Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines","source_id_and_acronym":"NCT02432378","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX","pipe":"","alterations":" ","tags":["IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Suspended","enrollment":" Enrollment 25","initiation":"Initiation: 09/04/2015","start_date":" 09/04/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-30"},{"id":"a2dce45d-64bf-4128-876e-4a25b3b1a037","acronym":"","url":"https://clinicaltrials.gov/study/NCT01059786","created_at":"2021-01-18T04:10:26.425Z","updated_at":"2024-07-02T16:35:06.574Z","phase":"Phase 2","brief_title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","source_id_and_acronym":"NCT01059786","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD22 • IL2RA • ITGAE • ITGAX • ISG20","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD22 • IL2RA • ITGAE • ITGAX • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • pentostatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-01"},{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"6817ade8-2b47-4eca-9afd-b28ec20d68bb","acronym":"MARSUN","url":"https://clinicaltrials.gov/study/NCT06006117","created_at":"2023-08-23T16:10:50.844Z","updated_at":"2024-07-02T16:35:35.484Z","phase":"Phase 3","brief_title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","source_id_and_acronym":"NCT06006117 - MARSUN","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD200 • ITGAX","pipe":" | ","alterations":" CD200 expression","tags":["CD200 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD200 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • bendamustine • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2023-09-27"},{"id":"d3399d53-3142-4fb8-8731-3da5f0cf0026","acronym":"TITAN-RCC","url":"https://clinicaltrials.gov/study/NCT02917772","created_at":"2021-08-04T19:53:08.805Z","updated_at":"2025-02-25T14:36:42.250Z","phase":"Phase 2","brief_title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT02917772 - TITAN-RCC","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-10-06"},{"id":"dcd072e3-9fd1-4a14-9cf9-d662805f13a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01668849","created_at":"2021-01-18T07:13:06.579Z","updated_at":"2024-07-02T16:36:05.856Z","phase":"Phase 1","brief_title":"Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer","source_id_and_acronym":"NCT01668849","lead_sponsor":"University of Louisville","biomarkers":" CD8 • ITGAM • ITGAX","pipe":"","alterations":" ","tags":["CD8 • ITGAM • ITGAX"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 08/02/2012","start_date":" 08/02/2012","primary_txt":" Primary completion: 05/25/2022","primary_completion_date":" 05/25/2022","study_txt":" Completion: 06/03/2022","study_completion_date":" 06/03/2022","last_update_posted":"2022-08-09"},{"id":"46a60911-95ea-49e1-9116-ac29702f16ef","acronym":"BioUV2017","url":"https://clinicaltrials.gov/study/NCT03340155","created_at":"2021-01-18T16:29:55.696Z","updated_at":"2024-07-02T16:37:16.400Z","phase":"","brief_title":"Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases","source_id_and_acronym":"NCT03340155 - BioUV2017","lead_sponsor":"Medical University of Graz","biomarkers":" CD8 • IL2RA • CD163 • PTPRC • NCAM1 • CD68 • FOXP3 • ITGAE • ITGAX • ISG20","pipe":"","alterations":" ","tags":["CD8 • IL2RA • CD163 • PTPRC • NCAM1 • CD68 • FOXP3 • ITGAE • ITGAX • ISG20"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 10/30/2017","start_date":" 10/30/2017","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2017-11-13"},{"id":"24dd0f83-5501-426c-b044-d1a1395f1d4b","acronym":"IMAGE","url":"https://clinicaltrials.gov/study/NCT02176447","created_at":"2021-01-18T10:08:36.865Z","updated_at":"2024-07-02T16:37:28.245Z","phase":"","brief_title":"Age-related Changes in the Immune System and Their Impact on Elderly Breast Cancer","source_id_and_acronym":"NCT02176447 - IMAGE","lead_sponsor":"Universitaire Ziekenhuizen Leuven","biomarkers":" HER-2 • ER • CD20 • CDKN2A • CD123 • NCAM1 • CD14 • ITGAM • IL3RA • ITGAX","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • CD20 • CDKN2A • CD123 • NCAM1 • CD14 • ITGAM • IL3RA • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2016-10-25"}]